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In vivo analysis of highly conserved Nef activities
in HIV-1 replication and pathogenesis
Richard L Watkins, Wei Zou, Paul W Denton, John F Krisko, John L Foster* and J Victor Garcia*

Abstract
Background: The HIV-1 accessory protein, Nef, is decisive for progression to AIDS. In vitro characterization of the
protein has described many Nef activities of unknown in vivo significance including CD4 downregulation and a
number of activities that depend on Nef interacting with host SH3 domain proteins. Here, we use the BLT humanized mouse model of HIV-1 infection to assess their impact on viral replication and pathogenesis and the selection
pressure to restore these activities using enforced in vivo evolution.
Results: We followed the evolution of HIV-1LAI (LAI) with a frame-shifted nef (LAINeffs) during infection of BLT mice.
LAINeffs was rapidly replaced in blood by virus with short deletions in nef that restored the open reading frame
(LAINeffsΔ-1 and LAINeffsΔ-13). Subsequently, LAINeffsΔ-1 was often replaced by wild type LAI. Unexpectedly,
LAINeffsΔ-1 and LAINeffsΔ-13 Nefs were specifically defective for CD4 downregulation activity. Viruses with these
mutant nefs were used to infect BLT mice. LAINeffsΔ-1 and LAINeffsΔ-13 exhibited three-fold reduced viral replication
(compared to LAI) and a 50% reduction of systemic CD4+ T cells (>90% for LAI) demonstrating the importance of CD4
downregulation. These results also demonstrate that functions other than CD4 downregulation enhanced viral replication and pathogenesis of LAINeffsΔ-1 and LAINeffsΔ-13 compared to LAINeffs. To gain insight into the nature of these
activities, we constructed the double mutant P72A/P75A. Multiple Nef activities can be negated by mutating the SH3
domain binding site (P72Q73V74P75L76R77) to P72A/P75A and this mutation does not affect CD4 downregulation.
Virus with nef mutated to P72A/P75A closely resembled the wild-type virus in vivo as viral replication and pathogenesis
was not significantly altered. Unlike LAINeffs described above, the P72A/P75A mutation had a very weak tendency to
revert to wild type sequence.
Conclusions: The in vivo phenotype of Nef is significantly dependent on CD4 downregulation but minimally on the
numerous Nef activities that require an intact SH3 domain binding motif. These results suggest that CD4
downregulation plus one or more unknown Nef activities contribute to enhanced viral replication and pathogenesis
and are suitable targets for anti-HIV therapy. Enforced evolution studies in BLT mice will greatly facilitate identification
of these critical activities.
Keywords: HIV-1, Nef, Replication, Pathogenesis, BLT humanized mice, Mutation

Background
Patients infected with nef-defective HIV-1, have strongly
attenuated viral replication and pathogenesis [1-4]. In
vitro studies have defined numerous Nef activities but
how this 206 amino acid protein has such a major effect
on the outcome of HIV-1 infection in patients is unknown [5-9]. One view of Nef’s overall impact on HIV-1
infection is that there is a cumulative effect of multiple
* Correspondence: john_foster@med.unc.edu; victor_garcia@med.unc.edu
Division of Infectious Diseases, Center for AIDS Research, 2042 Genetic
Medicine, University of North Carolina, Campus Box 7042, Chapel Hill, NC
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activities to achieve high viral loads resulting in the development of AIDS [10,11]. In support of this view, a
number of Nef activities have been found to be conserved in monkey, ape and human immunodeficiency viruses [12-17]. A difficulty with this interpretation is that
there are so many Nef activities that the effect of any
given activity on replication and pathogenesis would be
small. Alternatively, one or a few Nef functionalities may
be the major contributors to viral replication and pathogenesis. In this regard CD4 downregulation, a highly
conserved Nef function, is of particular interest. Ex vivo
studies with activated peripheral blood T cells and cultures
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of tonsil tissue support a dominant role for CD4 downregulation in establishing high rates of viral replication
[18-20]. Another factor that may be critical is the SH3
domain binding site in Nef’s polyproline helix [21-23].
This ten amino acid segment (PVRPQVPLRP) is the
most highly conserved stretch of amino acids in the protein [24]. Evidence exists for SH3 domain binding site
involvement with enhanced viral replication [21,23,25],
cytotoxic effects [26-30], activation of Hck [31] and antagonism of host immune responses [32-36]. Nef structure/function studies have documented that the CD4
downregulation activity and the SH3 domain protein
dependent activities are genetically distinct [21,37,38].
To gain greater understanding of the roles of Nef’s diverse activities during HIV-1 replication we have employed
the BLT humanized mouse model. This model has stable
reconstitution of a full spectrum of human immune cells
and has been used to investigate a number of different aspects of HIV-1 infection [39-44]. With regard to Nef, we
have previously compared the replicative properties of
HIV-1LAI (LAI) and LAI with two large deletions in nef
coding sequence (LAINefdd) in BLT humanzed mice [44].
LAI exhibited high levels of viral replication and near total
depletion of CD4+ T cells in blood and tissues, as well as,
depletion of CD4+ CD8+ thymocytes from the human
thymic organoid. LAINefdd had significantly reduced viral
replication and dramatically reduced capacity for inducing
CD4+ T cell and CD4+ CD8+ thymocyte loss [44]. However, one important aspect of HIV-1 infection of BLT humanized mice that has not yet been investigated is the
ability of nef to evolve during HIV-1 infection. In patients,
HIV-1 nef extensively mutates resulting in tremendous sequence diversity but it has not been possible to clearly relate these changes to Nef activities or the pathogenic
potential of the virus [24,45-49]. Here, we investigate three
critical features of Nef’s role during HIV-1 infection: 1)
the ability of the virus to mutate nef sequences to gain enhanced replicative fitness, 2) the role of CD4 downregulation in viral replication and pathogenesis and 3) the
importance of Nef’s interactions with host SH3 domain
proteins in replication and pathogenesis. We find that Nef
induced CD4 downregulation is highly significant for active viral replication and pathogenesis. In addition, there
are unidentified function(s) that contribute to viral replication and/or CD4+ T cell depletion and are necessary for
Nef ’s full pathogenic potential. Importantly, this latter
function or functions does not depend on interactions
with host cell SH3 domain proteins.

Results
With the exceptions of vif and pol, the ability of HIV-1
to correct defective genes in vivo and regain function
has not been investigated [50,51]. Determining the selection pressure for Nef functions is a key component for
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characterizing the overall importance of Nef and the
phenotypic contribution of its individual activities. In
addition, it provides an opportunity to use enforced selection to discern what structural/functional motifs of
Nef are important in vivo. To address the mutational response of the virus to a defective nef, we generated an
inactivating mutation by filling in the 5′ four-base overhang generated by the XhoI restriction endonuclease at
codon 35 with Klenow (Figure 1A and Additional file 1).
This insertion resides 5′ of the polypurine tract and does
not alter the synthesis of gag encoded proteins (Figure 1B)
or alter the in vitro replication properties of the virus
(Figure 1C).
LAI and the nef frame-shifted LAI (LAINeffs) were
injected intravenously (iv, 360,000 TCIU) into BLT mice.
Three LAI infected mice were monitored over eight
weeks for virus in the blood. These mice had peak viral
loads of 12.2 ± 4.7 × 106 copies of viral RNA. No changes
were observed in nef sequence after eight weeks of the infection (Figure 2A). The LAINeffs inoculated mice were
also monitored longitudinally for the presence of virus in
plasma. LAINeffs infected mice exhibited active viral replication with peak viral loads of 2.26 ± 0.72 × 106 copies of
viral RNA per ml of blood (n = 7). We sequenced nef from
viral RNA in blood from two to eight weeks post-infection
and found that the frame-shifted LAINeffs (designated
“+4”) was initially replaced by one of two nef sequences
with restored open reading frames (Figure 2A). One
mouse (LAINeffs 1) had a thirteen base deletion downstream of the original four base insertion (Δ-13). In the
other six cases (LAINeffs 2–7), the nef coding sequence
also retained the four base insertion but lost one base in a
run of five adenines just downstream of the original insertion site (Δ-1). The original LAINeffs (+4) was not detectable in blood by five weeks post infection in any of the
seven mice. In two mice, and by a slower process, wild
type nef appeared by 4–7 weeks (LAINeffs 4, 5). After
eight weeks, four mice (LAINeffs 3, 4, 5 and 6) were predominantly infected with a virus containing wild type nef
(not shown). In summary, in the blood of all of the mice
inoculated with LAINeffs the original defective nef was replaced by a nef mutant that restored the open reading
frame. Sequences determined at eight weeks yielded four
mice with exact removal of the four base insertion (WT),
two mice with Δ-1 and one mouse with Δ-13. These results support the conclusion that a strong positive selection exists for a functioning nef.
The amino acid sequences of the restored nefs are reported in Figure 2B. The changes in Nef sequence resulting from the one base deletion (LAINeffsΔ-1) and the
thirteen base deletion (LAINeffs-13) were the replacement
of three amino acids (DLE, 36–38) in wild type LAINef
with four missense amino acids (SRPG) and the replacement of ten wild type amino acids (DLEKHGAITS, 36–45)
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Figure 1 A frame shift in nef ablates expression of Nef but does not affect viral replication. (A) Upper Panel, Left, Schematic representation
of wild type LAI (WT LAI) is presented. Nucleotides 8390 to 9010 in NCBI accession number, K02013, represent the nef coding sequence. Lower
Panel, Left, A schematic of frame shifted nef (LAINeffs) is presented. The insertion of GATC following nucleotide 8494 is indicated. PPT, polypurine
tract. Upper Panel, Right, Flow chart describing the generation of the GATC insertion is presented. (B) The frame shift in nef eliminates Nef
expression but does not alter the expression of Gag. nef (α-Nef) and gag (α-p24) encoded proteins were detected by Western blot analysis of
293T producer cell lysates. GAPDH (α-GAPDH) is a protein loading control. (C) A3.01 cells were infected with LAI or LAINeffs at a multiplicity of
infection of 0.05 and viral production was followed for 20 days with ELISA for p24gag.

with seven missense amino acids (SRPGKTC), respectively
(Figure 2B). The sequencing data suggested that virus with
fsΔ-1 and fsΔ-13 nefs had a strong replicative advantage
over the nef-defective virus. However, the replacement of
LAINeffsΔ-1 with wild type (WT) virus in four mice further suggests a replicative advantage for wild type nef over
revertant nefs. Based on these in vivo findings, we were interested in characterizing the in vitro activities of the Δ-1
and Δ-13 mutant Nefs.
In vitro functional analysis of nef mutants that evolved
in vivo

To assess in vitro phenotypes of the Nefs expressed by
LAINeffsΔ-1 and LAINeffsΔ-13, we transferred the coding sequences into the retroviral expression plasmid,
pLXSN, and produced retroviral vectors [52]. CEM T
cells expressing wild type and mutant Nefs were assayed
for level of expression, CD4 downregulation and MHC
Class I (MHCI) downregulation activities (Figure 3A).

The mutant forms of Nef were expressed at the same
level as wild type Nef (Figure 3A, Upper Panel, α-Nef ).
Flow cytometric analysis of cell surface CD4 and MHCI
expression of CEM T cells that were transduced to express LAI Nef yielded the well-known patterns for the
downregulation of these proteins (Figure 3A, Lower
Panel, [21,52,53]). Both LAI NeffsΔ-1 and LAI NeffsΔ13 proteins were fully active for MHCI downregulation
but devoid of CD4 downregulation activity. To assess
the effect of the two mutations on Nef’s interaction with
p21 activated protein kinase (PAK2), we expressed the
NeffsΔ-1 and NeffsΔ-13 proteins from pcDNA3.1 in
transfected 293T cells. We determined the capacity of
these Nefs to activate PAK2 using an in vitro kinase
assay (IVKA, [21,54,55]). Again, both mutant proteins
were expressed at the same level as wild type LAI Nef
(Figure 3B, α-Nef ) and both proteins activated PAK2 although at a reduced level for LAI NeffsΔ-13 (Figure 3B,
α-PAK2 IVKA). We also generated the proviral clones,
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Figure 2 LAINeffs mutates to have one of three nefs with an open reading frame. (A) At several time points during the eight week
infection, viral RNA was reverse transcribed from plasma. After amplification by PCR, nef was sequenced. By four weeks, six of seven mice
exhibited nef sequence with a one base deletion just downstream of the four base insertion in a run of five adenines. This one base deletion
(Δ-1) restored the nef reading frame. In the remaining mouse, a 13 base deletion occurred downstream of the four base insertion (Δ-13) which
also restored the nef open reading frame. Three of the seven mice had a mixture of two different sequences in plasma which are indicated by
the “majority sequence/the minority sequence.” By seven weeks, there were two mice with reversions to wild type sequence (WT) by the removal
of four inserted bases from CTCGATCGAG to yield CTCGAG. +4, nef with the original four base insertion intact. (B) The conceptual translations of
the LAINeffsΔ-1 and LAINeffsΔ-13 mutated nefs are aligned with wild type LAI Nef amino acid sequence. Bold indicates missense amino acids
encoded by LAINeffsΔ-1 and LAINeffsΔ-13.

pLAINeffsΔ-1 and pLAINeffsΔ-13, to characterize the
enhancement of infectivity function of these Nefs. Virus
was produced from transfected 293T cells and assayed
with HeLa MAGI indicator cells. In this single infection
assay, a reduction in the number of infected cells per ng
of virion p24gag is observed for LAINeffs relative to LAI
(Figure 3C). LAINeffsΔ-1 and LAINeffsΔ-13 both exhibited higher infectivities than LAINeffs in this assay but
were not significantly different from LAI (Figure 3C).
Finally, in Figure 3D, the capacities of LAINeffsΔ-1 and
LAINeffsΔ-13 to replicate in A3.01 cells were observed
to be the same as LAI (Figure 3D). On the basis of this
data, we concluded that LAINeffsΔ-1 and LAINeffsΔ-13

exhibited a specific loss of the CD4 downregulation activity and were potentially useful to investigate the impact of CD4 downregulation by Nef on HIV-1 infection
in BLT mice. However, the question remained whether
these nefs could revert to wild type sequence in vivo as
four of seven mice infected with LAINeffs had predominantly the wild type nef sequence in blood after eight
weeks (Figure 2A). It should be noted that reversion of
the ֹ Δ-1 mutation to wild type would require two steps,
a four-base deletion and a one base insertion of adenosine. We judged this two-step process to be unlikely to
occur within the time frame of the experiments. Accordingly, the wild type nefs found in four of the seven mice
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(See figure on previous page.)
Figure 3 LAINeffsΔ − 1 and LAINeffsΔ − 13 encode Nefs that are specifically defective for downregulating surface expression of CD4.
(A) Nefs encoded by LAINeffsΔ-1, LAINeffsΔ-13 and LAI were expressed in CEM cells following transduction with retroviral vectors (LXSN). Upper
Panel, A Western blot demonstrates LAI NeffsΔ-1 and LAI NeffsΔ-13 were expressed at comparable levels as wild type (α-Nef). LXSN and
LXSNNeffs served as negative controls. GAPDH is a protein loading control (α-GAPDH). Lower Panel, CEM cells expressing LAI Nef, LAI Neffs, LAI
NeffsΔ-1 and LAI NeffsΔ-13 were analyzed by flow cytometry for cell surface CD4 and MHC Class I (MHCI) expression. LXSNLAINef was the
positive control. LXSN and LXSNLAINeffs were negative controls. Percentage of cells in each quadrant out of total cells is indicated. (B) Nefs
encoded by LAI, LAINeffsΔ-1 and LAINeffsΔ-13 were expressed in transfected 293T cells. Control, 293T cells transfected with empty vector. Upper
Panel, Lysates from transfected cells were analyzed by Western blot (α-Nef). Lower Panel, Total p21 activated protein kinase-2 (PAK2) in lysates of
transfected cells lysates were immunoprecipitated with anti-PAK2 antiserum (α-PAK2) and analyzed by the in vitro kinase assay (IVKA). Control cells had
no activated PAK2. Arrow, autophosphorylated PAK2. (C) pLAI, pLAINeffs, pLAINeffsΔ-1 and pLAINeffsΔ-13 proviral clones were transfected into 293T cells
and virus harvested from the media. LAI, LAINeffs, LAINeffsΔ-1 and LAINeffsΔ-13 were titered using HeLa-MAGI indicator cells [82] and p24gag contents
were quantified by ELISA. Infectivities (blue cells per ng p24gag) from six determinations of each virus were normalized relative to LAI (100%). Significant
comparisons are indicated by lines and arrows above respective bars (*, p < 0.05). (D) A3.01 cells were infected with LAI, LAINeffsΔ-1 and LAINeffsΔ-13
at multiplicity of infection of 0.05 and viral production followed for 20 days with ELISA for p24gag.

by week eight may have been directly generated from the
frame-shifted nef in LAINeffs by the exact removal of the
four-base insertion (Additional file 1).
Infection of BLT humanized mice with in vivo generated
nef mutations

LAI, LAINeffsΔ-1 and LAINeffsΔ-13 were intravenously
injected (90,000 TCIU) into BLT mice. In Figure 4, the
positive control, wild type LAI, and the negative control,

uninfected mice (Naïve), are compared to LAINeffsΔ-1
and LAINeffsΔ-13 infected mice. In Figure 4A and C,
LAI inoculation was followed with rapid appearance of
viral RNA in blood and replication to high levels (peak
viral loads, 3.03 ± 0.54 × 106 copies viral RNA per ml of
plasma, n = 7). The time course for the infections with
LAINeffsΔ-1 and LAINeffsΔ-13 revealed a reduction in
viral replication compared to LAI (Figure 4A and C).
The average peak viral load (in millions of RNA copies

A

B

C

D

Figure 4 Viral load analysis and peripheral blood CD4+ T cell depletion in mice infected with LAI. (A) Viral loads (copies of LAI RNA per
milliliter of plasma) of BLT humanized mice exposed to 90,000 TCIU of LAI or LAINeffsΔ-1 were plotted. Uninfected mice (Naïve) served as
negative controls (open circle, n = 8); LAI (filled circle, n = 7); and LAINeffsΔ-1 (filled square, n = 4). (B) Plot of percent peripheral blood CD3+ T
cells expressing CD4. Naïve mice, LAI and LAINeffsΔ-1 as in (A). (C) Viral loads were plotted following inoculation of 90,000 TCIU of LAI or
LAINeffsΔ-13. Naïve mice as negative controls (open circle, n = 8); LAI (filled circle, n = 7); and LAINeffsΔ-13 (filled triangles, n = 4). (D) Plot of
percent peripheral blood CD3+ T cells expressing CD4. Naïve mice, LAI and LAINeffsΔ-13 as in (C).
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per ml of peripheral blood) for LAINeffsΔ-1 was 1.19 ±
0.26 (n = 4) which was significantly different from LAI
(Figure 4A, 3.03 ± 0.54 (n = 7); p = 0.0242). Similarly, in
Figure 4C, the average peak viral load for LAINeffsΔ-13
was lower than LAI (0.93 ± 0.23 (n = 4); p = 0.0061).
Thus, there appears to be about a threefold reduction in
peak viral load relative to wild type for LAINeffsΔ-1 and
LAINeffsΔ-13.
During infection with LAI, CD4+ T cell levels in blood
were dramatically reduced (Figure 4B and D) while CD4+
T cells in the blood of uninfected mice were maintained at
approximately 80% of total blood T cells (Figure 4B and
D). For LAI, the average time to reduce CD4+ T cells to
50% of total blood T cells was 21.6 ± 2.4 days post infection (dpi, n = 7). For mice inoculated with LAINeffsΔ-1 or
LAINeffsΔ-13, an intermediate loss of CD4+ T cells was
evident (Figure 4B and D). The time for CD4+ T cells in
blood to decline to 50% of total T cells was determined
and compared to LAI (Figure 4B and D). As noted, LAI
gave 21.6 ± 2.4 dpi (n = 7) which was significantly shorter
than LAINeffsΔ-1 at 65.1 ± 13.4 dpi (n = 4, p = 0.0106) and
LAINeffsΔ-13 at 52.5 ± 13.5 dpi (n = 4, p = 0.0294). LAINeffsΔ-1 and LAINeffsΔ-13 infected mice were not statistically different from each other. Together, the results
from Figure 4 document an intermediate in vivo Nef
phenotype for LAINeffsΔ-1 and LAINeffsΔ-13.
We have previously reported the phenotypes of LAI
and LAI with a totally inactivated nef (LAINefdd, [44]).
The observation that LAI expressing a Nef specifically
defective for CD4 downregulation has an intermediate
phenotype not expected based on previous reports [18,19,56].
In support of this conclusion, we also observed that a partial loss of CD4+ T cells from blood is established by six
weeks. At this time point, the percent of CD4+ T cells in
LAINeffsΔ-1 and LAINeffsΔ-13 infected mice were significantly lower than in Naïve mice but significantly higher
than in LAI-infected mice (Figure 4B and D). For LAINeffsΔ-1 inoculated mice, the percent CD4+ T cells of
total T cells present in blood was 55.4 ± 3.3 (n = 4) compared to 77.5 ± 2.8 (n = 4) for Naïve (Figure 4B) with p =
0.0286. For LAINeffsΔ-13 inoculated mice, the percentages were 47.0 ± 11.7 (n = 4) versus 77.5 ± 2.8 (n = 4) with
p = 0.0286. Also at six weeks, LAINeffsΔ-1 and LAINeffsΔ-13 infected mice had higher percentages of CD4+
T cells than LAI infected mice (Figure 4B and D). Percent
of CD4+ T cells for LAI was 12.5 ± 4.5 (n = 6), versus 55.4 ±
3.3 (n = 4, p = 0.0095) for LAINeffsΔ-1. Percent of CD4+
T cells for LAI versus LAINeffsΔ-13 was 12.5 ± 4.5 (n = 6)
versus 47.0 ± 11.7 (n = 4, p = 0.0190).
At eight weeks, CD4+ T cells in blood of LAI infected
mice are nearly depleted while Naïve mice maintained
CD4+ T cells at approximately 80% of total CD4+ T cells
(Figure 4B and D, [44,57]). It was of interest to allow the
LAINeffsΔ-1 and LAINeffsΔ-13 infections to continue
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past eight weeks to determine if these viruses would slowly
deplete CD4+ T cells from blood. By 14 weeks, substantial
levels of CD4+ T cells were still evident in blood for both
viruses which emphasizes the persistence of the partial
Nef phenotype in the absence of CD4 downregulation
(Figure 4B and D).
Systemic loss of CD4+ T cells in BLT humanized mice
infected with LAINeffsΔ-1 and LAINeffsΔ-13

We previously observed that systemic loss of human
CD4+ T cells from organs closely paralleled loss of human CD4+ T cells from blood during infection with wild
type (LAI) and nef-defective (LAINefdd) virus [44,57].
For LAINeffsΔ-1 and LAINeffsΔ-13 infected mice, we
also determined that the loss of CD4+ T cells in peripheral
blood is matched by the loss of these cells from bone marrow, lymph node, liver, lung and spleen (Figure 5A). Statistical analysis of Naïve versus LAI, LAINeffsΔ-1 and
LAINeffsΔ-13 infected mice demonstrated significant
losses in the percent of CD4+ T cells in the five tissues
(fifteen comparisons to Naive, all gave p < 0.05). Also,
the fraction of total T cells that were CD4+ was consistently higher in LAINeffsΔ-1 infected mice compared to
LAI (all five comparisons, p < 0.05). In the case of LAINeffsΔ-13 versus LAI, three of five organs had statistically higher levels of CD4+ T cells in LAINeffsΔ-13
infected mice, with the higher levels of CD4+ T cells not
reaching statistical significance for bone marrow and
lymph node. The comparisons between LAINeffsΔ-1
and LAINeffsΔ-13 infected mice were not significantly
different in any tissue. Therefore, the partial reduction
of CD4+ T cells in blood seen with LAINeffsΔ-1 and
LAINeffsΔ-13 infection is systemic.
We previously reported a devastating impact of LAI
infection on CD4+ CD8+ thymocytes. However, LAI
lacking a functional nef failed to reduce double positive
thymocytes [44]. In Figure 5B, drastic depletion of CD4+
CD8+ thymocytes was confirmed following inoculation
with LAI. Intermediate losses were observed with LAINeffsΔ-1 and LAINeffsΔ-13 (Naive, 76.3 ± 3.0%; LAI, 1.7
± 1.2%; LAINeffsΔ-1, 35.0 ± 17.1%; LAINeffsΔ-13, 29.3 ±
10.2%). On the basis of the above results, we conclude
that the partial losses of LAINeffsΔ-1 and LAINeffsΔ-13
found for CD4+ T cells appeared to extend to CD4+ CD8+
thymocytes as well.
The mechanistic interpretation of the intermediate
phenotype of the LAINeffsΔ-1 and LAINeffsΔ-13 viruses
depends on the status of the sequence of nef. We sequenced nef in plasma virion RNA of LAINeffsΔ-1 and
LAINeffsΔ-13 and found no reversions over the course
of infection. Specifically, for LAINeffsΔ-1, the four base
insertion and the Δ-1 deletion remained intact. For LAINeffsΔ-13, the four base insertion and the thirteen base
deletion remained intact. There were no second site
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Figure 5 Analysis of CD4+ T cells from tissues in mice exposed to LAI, LAINeffsΔ − 1 or LAINeffsΔ − 13. (A) Percent CD4+ T cells of total T
cells in five organs from un-exposed BLT mice (Naive, n = 8) were compared to groups of BLT mice exposed to one of three viruses: LAI (n = 6),
LAINeffs Δ-1 (n = 4), or LAINeffs Δ-13 (n = 4). Statistical comparisons reaching significance are indicated by lines and arrows above respective bars
(*, p < 0.05). (B) The same groups as in (A) were compared for CD4+CD8+ double positive thymocytes relative to total thymocytes.

mutations present in nef either (not shown). The absence of wild type nef sequence from LAINeffsΔ-1 and
LAINeffsΔ-13 infected BLT mice implies the stability of
the phenotypic properties of these two nefs during infection. This failure of nefs from LAINeffsΔ-1 and LAINeffsΔ-13 to revert to wild type supports the hypothesis
that the appearance of wild type nef sequence found in
four of seven mice (Figure 2) infected with LAINeffs was
the result of an exact four base deletion and not a twostep removal of the four base insertion plus a one base
addition (Additional file 1). Therefore, our investigations
of LAINeffsΔ-1 and LAINeffsΔ-13 demonstrate that
LAIs stably lacking Nef’s CD4 downregulation activity
have the in vivo phenotype of a reduced capacity for
viral replication, for CD4+ T cell depletion and for CD4+
CD8+ thymocyte depletion relative to LAI [44].
LAI, LAINeffsΔ-1 and LAINeffsΔ-13 and systemic T cell
activation

One explanation for the intermediate infection phenotypes
of LAINeffsΔ-1 and LAINeffsΔ-13 would be an inability of
these mutated HIV-1 to induce systemic T cell activation
[58,59]. It has been previously reported that naïve BLT mice
have approximately 2% of CD8+ T cells that are CD38+
HLA-DR+ double positive in blood. Infection with LAI or
LAINefdd elevates this fraction to approximately 8%
[42,44]. We observed similar effects of LAINeffsΔ-1 and
LAINeffsΔ-13 infection on T cell activation. At six weeks
post infection, LAINeffsΔ-1 and LAINeffsΔ-13 were determined to have 8.2 ± 3.5% (n = 4) and 6.1 ± 2.3% (n = 4)
CD38+ HLA-DR+ double positive CD8+ T cells in blood,

respectively. Thus, LAINeffsΔ-1 and LAINeffsΔ-13 exhibit
the same enhancements of peripheral blood T cell activation as LAI and LAINefdd.
The role of SH3 domain dependent activities on LAI
infection of BLT mice

A large number of diverse activities of Nef have been
shown to be dependent on the highly conserved SH3 domain binding site. We considered the possibility that these
activities may account for the observed selective advantage
of the LAINeffsΔ-1 and LAINeffsΔ-13 over LAINeffs despite the absence the CD4 downregulation activity. SH3
domain-binding dependent activities are blocked by mutating two key prolines in Nef’s polyproline helix (P72A/
P75A, [7,22]). To investigate the role of the P72A/P75A
mutant Nef in vivo we generated isogenic, replication competent LAINefP72A/P75A. In 293T cells, LAINefP72A/
P75A expressed similar levels of Nef and p24gag compared
to LAI (Figure 6A) and actively replicated in A3.01 T cells
(Figure 6B). We assayed the enhancement of virion infectivity for LAI and LAINefP72A/P75A and observed the expected loss of this activity for the SH3 domain binding
site mutant (Figure 6C, [21,25,37]). Also, we expressed the
mutated nef from LAINefP72A/P75A with the retroviral
vector, LXSN, in CEM T cells and found it to be functional
for CD4 downregulation but consistent with previous reports largely defective for MHCI downregulation (Figure 6D
[32,33,60]). On the basis of these results, we concluded that
infecting BLT mice with LAINefP72A/P75A would distinguish between the phenotypic impacts of SH3 domain binding protein dependent activities and CD4 downregulation.
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Figure 6 LAINefP72A/P75A replicates in A3.01 T cells and is functional for CD4 downregulation. pLAI, pLAINeffs and pLAINefP72A/P75A
proviral clones were transfected into 293T cells and virus harvested from the media. (A) Nef (α-Nef) and p24gag (α-p24) proteins were detected by
Western blot analysis of 293T producer cell lysates. Control is non-transfected 293T cells. GAPDH (α-GAPDH) is a protein loading control. (B) A3.01
cells were infected with LAI and LAINefP72A/P75A at multiplicity of infection of 0.05 and viral production followed for 20 days with ELISA for
p24gag. (C) LAI, LAINeffs and pLAINefP72A/P75A were titered using HeLa-MAGI indicator cells [82] and p24gag quantitated by ELISA. Infectivities
were normalized to LAI (100%). (D) Nefs encoded by LAINefP72A/P75A and LAI were expressed in CEM cells following transduction with retroviral
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BLT mice were infected with 90,000 TCIU of LAINefP72A/P75A mutant virus (Figure 7). Under these experimental conditions, a 1.9-fold higher peak viral load was
observed for LAINefP72A/P75A versus LAI (Figure 7A).
This difference was not statistically different (5.83 ± 1.84 (n
= 4) versus 3.03 ± 0.54 (n = 7); p = 0.1091). In addition, the
P72A/P75A Nef mutant and the wild type virus showed a
similar time course for reduction of peripheral blood CD4+
T cells to 50% of total T cells in blood with LAINefP72A/
P75A at 29.5 ± 4.1 dpi (n = 4) versus LAI at 21.6 ± 2.4 dpi

(n = 7); p = 0.1554 (Figure 7B). These results indicate that a
functional SH3 domain binding site in Nef is not required
in vivo for either high levels of virus replication or for CD4+
T cell depletion.

Systemic depeltion of CD4+ T cells and thymocytes by
LAINefP72A/P75A

In transgenic mice, it has been reported that expression
of HIV-1 Nef from a CD4 promoter is cytotoxic to CD4+
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residual CD4+ T cells in mice infected with LAI versus LAINefP72A/P75A were not significantly different (Figure 8A).
CD4+ CD8+ thymocytes in the human thymic organoid
were also analyzed. We found that these cells were efficiently depleted by LAINefP72A/P75A (Figure 8B). We,
therefore, conclude that contrary to expectations the
mutation, P72A/P75A has little to no effect on the systemic depletion of CD4+ T cells or CD4+ CD8+ thymocytes in vivo.
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T cells in multiple organs [61]. In addition, this cytotoxic
effect is lost when the polyproline helix is mutated [27].
Therefore, we determined the impact LAINefP72A/P75A
infection in BLT mice on CD4+ T cells in bone marrow,
lymph node, liver, lung and spleen (Figure 8A). LAI and
LAINefP72A/P75A effectively depleted CD4+ T cells. All
differences in levels of CD4+ T cells between Naïve mice
and either LAI or LAINefP72A/P75A mice are statistically
significant. In contrast, comparisons between the levels of

Figure 8 Analysis of CD4+ T cells from tissues from mice exposed to LAI or LAINefP72A/P75A. (A) Percent of CD4+ T cells out of total T
cells from bone marrow, lymph node, liver, lung and spleen from unexposed BLT mice (Naive, n = 8) were compared to groups of BLT mice
exposed to LAI (n = 7) or LAINefP72A/P75A (n = 4). Statistical comparisons reaching significance are indicated by lines and arrows above
respective bars (*, p < 0.05). (B) The same analysis as in (A) is presented for CD4+CD8+ double positive thymocytes relative to total thymocytes.
Statistical comparisons reaching significance are indicated by lines and arrows above respective bars (*, p < 0.05).
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In vivo selection pressure to correct the P72A/P75A
mutation is weak

Our conclusion that an intact SH3 domain binding site is
not a major factor in determining the level of HIV-1 replication suggests that there is little or no selection pressure
for reversion of the alanines to prolines. LAINefP72A/
P75A virion RNA from plasma of the LAINefP72A/P75A
infected mice from Figures 7 and 8 was processed for
sequencing. No nucleotide changes in nef were noted
through six weeks for the entire nef sequence from all four
mice. Also, no changes were seen to fourteen weeks for
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three of four mice (not shown). At week eight, however,
nef sequence from one of the four mice infected with the
P72A/P75A mutant virus had a clear shift from guanine
to mostly cytosine at the first base of the codon for position 75 (Figure 9). This transversion converted the mutant alanine codon (GCT) to the wild type proline codon
(CCT). Even though the CD4+ T cells in LAINefP72A/
P75A infected mice were nearly depleted, we continued
monitoring the infection past eight weeks to determine
if further mutations would occur during LAINefP72A/
P75A infection. Interestingly, for the mouse presented

Week 2

Week 10

Week 4

Week 12

Week 6

Week 14

Week 8

Figure 9 Delayed partial reversion of P72A/P75A. nef sequences were obtained from viral RNA in plasma of four LAINefP72A/P75A infected
mice from Figure 7. Only one of four mice had a change in nef sequence which is shown in the panels here. This was the reversion of the P75A
mutation back to proline. The delayed and limited appearance of this mutation may be the result of the low probability of a transversion (G to C)
coupled to a small enhancement of viral fitness. The twelve nucleotides encoding the SH3 domain binding motif core (P72Q73V74P75) are
presented. The wild type proline codons that were mutated to alanine are P72A (left panel headed by GCT) and P75A (right panel headed by
GCT). The replacement of guanine with cytosine that restores the P75 codon is seen in the right panels of weeks 8, 10, 12 and 14 headed with
CCT instead of GCT. Arrow, guanine mutated to cytodine. A, green; C, blue; G, black: T, red. The four codons presented are GCT, alanine; CCT,
proline; CAG, glutamine; GTA, valine.
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in Figure 9, the virus with an alanine codon at 72 and
proline codon at 75 completely replaced the input virus
but failed to revert the alanine codon at position 72
(Figure 9, Weeks 10–14). There were no other changes
in the nef sequence from this mouse (not shown). Since
no reversion to original SH3 domain binding site (P72/P75)
occurred within the eight week time frame, the high
levels of viral replication and peripheral blood CD4+ T
cell depletion could not be explained by appearance of
wild type virus. Thus, our results support a model where
CD4 downregulation plus one or a few additional
activities- not dependent on the SH3 domain binding
site- largely account for Nef ’s impact on viral replication
and/or pathogenesis. Loss of the capacity for SH3 domain binding has little effect on viral replication and
pathogenesis and exhibits at best a small reduction in
viral fitness.

Discussion
Previously, we established that there are large phenotypic differences between infection of BLT mice with
wild type LAI and the nef-defective LAINefdd in vivo
[44]. LAI replicates to high viral loads concomitantly
with aggressive and systematic depletion of CD4+ T cells
and CD4+ CD8+ thymocytes. LAINefdd exhibits 6–7
fold lower peak viral loads and has little to no capacity
to deplete CD4+ T cells or thymocytes [44]. These two
large effects of Nef make it feasible to characterize the
importance of Nef’s individual activities in BLT mice [5].
Here, we have demonstrated a third important property
of nef in the BLT mouse model- the ability to evolve and
restore functionality. Viruses expressing Nef proteins have
a decisive replicative advantage over the frame-shifted
LAINeffs and replace the nef-defective virus within a few
weeks. Hence, in seven mice, the input LAINeffs was lost
after four weeks with either LAINeffsΔ-1 (six mice) or
LAINeffsΔ-13 (one mouse) being the sole virus in peripheral blood. By eight weeks, four of seven mice further
evolved to be predominantly wild type virus.
The strong in vivo selection of LAINeffsΔ-1 and LAINeffsΔ-13 over LAINeffs led us to characterize these
in vivo selected mutant proteins in vitro. We discovered
them to be stable but with a total loss of CD4 downregulation activity. Three other in vitro Nef activities, MHCI
downregulation, PAK2 activation and enhancement of virion infectivity, remained intact. When BLT mice are infected with LAINeffsΔ-1 and LAINeffsΔ-13, we observed
an approximate 3-fold reduction in peak viral load and a
partial loss of CD4+ T cells and CD4+ CD8+ thymocytes
relative to that observed for LAI. These observations
suggest that the in vivo selection of the two viruses with
mutant nefs relative to LAINeffs relied on activities beyond CD4 downregulation. Conversely, the partial reduction of Nef effectiveness observed for LAINeffsΔ-1
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and LAINeffsΔ-13 demonstrates a significant role for
CD4 downregulation.
Our data provided evidence that there is selective
pressure for restoration of Nef activities other than CD4
downregulation. The identity of these activities is unknown.
We considered likely candidates to be one or more of the
SH3 domain binding site dependent activities. These activities include enhancement of virion infectivity [21,25,37],
PAK2 activation [21-23], upregulation of FasL and PD1
[28,29], activation of Hck [31], downregulation of MHCI
[32-34] and Lck-dependent activation Ras-Erk signaling to
promote the production of the T lymphocyte survival factor IL-2 [62,63]. We mutated prolines 72 and 75 to alanine
to prevent interactions between Nef and host cell SH3
domain proteins [21,22]. This mutation did not exhibit
a negative effect on Nef function in BLT mice. One explanation for this counter intuitive observation is that
high levels of replication and rapid reduction in CD4+ T
cell and CD4+ CD8+ thymocytes depend on only a few
Nef activities.
Future studies with BLT mice will investigate Nef activities
that are potentially responsible for the CD4 downregulationindependent aspects of Nef function in vivo. Possible activities include elevated secretion of exosomes, blocking
the anti-viral effect of autophagy and inhibition of ASK1
[64-69]. Conversely, these studies may lead to the important result that known Nef activities may not account for a
substantial portion of its impact on HIV-1 infection in vivo
[70]. In this regard, our mutational strategy of introducing
palindromic insertions into Nef coding sequence can be
extended to scan the protein for regions of special significance for viral replication and pathogenesis. The HIV-1/
BLT mice infection model described here is a feasible experimental platform for resolving these questions.

Conclusion
CD4 downregulation activity accounts for approximately
half of Nef’s capacity to enhance viral replication and
deplete CD4+ T cells and CD4+ CD8+ thymocytes. This
result is consistent with the high degree of conservation
of the CD4 downregulation activity. Identities of the Nef
activities that account for the remainder of Nef’s effects
are unknown. We found these latter activities which are
present in LAINeffsΔ-1 and LAINeffsΔ-13 provide the
virus a strong selective advantage over LAINeffs that is
fully defective for Nef expression. In addition, wild type
virus, expressing a fully active Nef, out-competes virus
expressing Nef specifically defective for CD4 downregulation. We tested the Nef activities dependent on the
SH3 domain binding site because the corresponding
amino acid sequence in the protein is highly conserved.
However, the virus with nef mutated for SH3 domain
binding was essentially wild type in its ability to enhance
viral replication and deplete CD4+ T cells and CD4+
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CD8+ thymocytes. Selective pressure for the mutant nef
to revert to wild type was low. It is critical to determine
which Nef activities or activities that do not depend on
SH3 domain protein binding yet have major impacts on
viral replication and pathogenesis.
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intact but introduces a four-base frame-shift after nef
codon 35 (Additional file 1). The one base deletion (8501)
and thirteen base deletion (8511–8523) found in nef sequences from LAINeffs infected mice were inserted into
pLAINef fs by site directed mutagenesis to produce pLAINeffsΔ-1 and pLAINeffsΔ-13, respectively.

Methods
Preparation of BLT humanized mice

BLT humanized mice were prepared as previously described [40-42,44,57,71-77]. Briefly, thymus/liver implanted
or NOD/SCID IL-2γ−/− mice (The Jackson Laboratories,
Bar Harbor, ME) were transplanted with autologous human
CD34+ cells isolated from fetal liver (Advanced Bioscience
Resources, Alameda, CA). Human reconstitution in the
peripheral blood of these mice was monitored periodically
by flow cytometry (FACSCanto; BD Biosciences). Mice
were maintained either at the Animal Resources Center,
UT Southwestern Medical Center at Dallas (UTSWMC)
or at the Division of Laboratory Animal Medicine, University of North Carolina at Chapel Hill (UNC-CH) in accordance with protocols approved by the UTSWMC or
UNC-CH Institutional Animal Care and Use Committees.
To ensure genetic diversity, fifteen different tissue donors were used to generate five groups of mice used for
the experiments presented in this manuscript. The overall level of engraftment for all the mice used in this
manuscript was 60.9% ± 3.2% (n = 27). None of the
groups (Naïve, LAI, LAINeffsΔ-1, LAINeffsΔ-13 and
LAINefP72A/P75A) had significantly different engraftment
levels compared to any of the other groups (p ≥ 0.1535).
All groups had at least two different human genetic backgrounds included in the evaluation of infection. LAINeffsΔ-1, LAINeffsΔ-13 and LAINefP72A/P75A infected
groups each shared a common donor with the LAI infected group.
Cell lines and culture conditions

HeLa Magi and TZM-bl cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Cellgro, Herndon, VA)
supplemented with 10% fetal bovine serum (FBS; Cellgro),
100 IU/ml of penicillin, 100 μg/ml streptomycin, and 2 mM
glutamine (Cellgro) in 10% CO2 at 37°C. Similarly, 293T
cells were cultured under the same conditions as TZM-bl
and HeLa Magi cells but in 5% CO2. The human CEM T
cell line was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone), 50 IU of
penicillin per ml, 50 μg streptomycin per ml, 2 mM L-glutamine and 1 mM sodium pyruvate in 10% CO2 at 37°C.
Proviral clones

The proviral clone, pLAI (accession # K02013), was described by Peden et al. [78]. pLAINeffs was constructed
to be defective for nef by cutting with XhoI, filling in
with Klenow and re-ligating. This leaves nef sequence

Virus production, exposure of BLT mice to HIV-1LAI and
HIV-1LAI with mutated nefs, tissue harvesting and flow
cytometric analyses

Stocks of LAI, LAINeffs, LAINeffsΔ-1, LAINeffsΔ-13
and LAINefP72A/P75A were prepared and titered as we
previously described [54,79]. Briefly, proviral clones were
transfected into 293T cells. Viral supernatant was collected
48 hours after transfection and diluted in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum, 100 IU penicillin/ml, 100 μg/ml streptomycin, and 2 mM glutamine. TZM-bl cells were infected
in 12-well tissue culture plates with 0.4 ml of virus at multiple dilutions in medium for two hours. Then, 1.0 ml of
supplemented DMEM was added and the plates incubated
overnight. Virus containing medium was removed the
next day, replaced with fresh DMEM plus 10% fetal bovine
serum and the incubation continued for 24 hours. The
cells were fixed and stained with 5-bromo-4-chloro-3indolyl-β-D-galactopyranoside (40 hours after first exposure to virus). Individual blue cells were counted directly to
determine infectious particles per ml (TCIU). Each titer of
these viral stocks was performed in triplicate and at least
two different titer determinations were performed for each
virus preparation.
Intravenous exposure of BLT mice with infectious
virus was conducted via tail vein injection with the indicated tissue culture infectious units (TCIU). Viral load
in peripheral blood of infected mice was monitored longitudinally by quantitative real-time PCR using Taqman
RNA to-CT™ 1-step kit from Applied Biosystems, USA
[72,73,80]. The sequences of the forward and reverse primers
and the Taqman probe for PCR were: 5′-CATGTTTTCAG
CATTATCAGAAGGA-3′, 5′-TGCTTGATGTCCCCCCAC
T-3′, and 5′-FAM CCACCCCACAAGATTTAAACACCAT
GCTAA-Q-3′, respectively.
CD4+ and CD8+ T cell levels were monitored by flow
cytometric analysis as previously described [40,57,76].
Immunophenotyping was performed on blood samples
collected longitudinally and on mononuclear cells isolated from tissues at harvest. Whole peripheral blood
(PB) from humanized mice was analyzed according to
the BD Biosciences Lyse/Wash protocol (Cat. No.
349202) as we have previously described [81]. Briefly,
following antibody labeling of whole blood, red blood
cells were lysed. The remaining cells were washed, fixed
and the sample was analyzed by flow cytometry. Tissue
mononuclear cell isolations and immunophenotyping
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analyses were also performed according to published
methods [40,57,76]. Flow cytometric gating for CD4 and
CD8 cell surface expression was performed as follows:
(step 1) forward and side scatter properties were utilized
to set a live cell gate; (step2) live cells were then analyzed for expression of the human pan-leukocyte marker
CD45; (step 3) human leukocytes were then analyzed for
hCD3 and (step 4) these T cells or thymocytes were analyzed for hCD4 and hCD8 expression.
The panel of antibodies for analysis of CD8+ T cells
double positive for CD38+ and HLA-DR+ was CD8 FITC
(SK1), HLA-DR, PE (TU36) or IgG2bκ PE, CD4 PerCP
(SK3), CD3 PE-Cy7 (SK7), CD38 APC (HB7) or IgG1κ
APC, and CD45 APC-Cy7 (2D1) (all purchased from BD
Biosciences). Gating was performed as follows: (step 1)
forward and side scatter properties were utilized to set a
live cell gate; (step 2) live cells were then analyzed for
expression of the human pan-leukocyte marker CD45;
(step 3) human leukocytes were then analyzed for CD3;
(step 4) T cells were analyzed for CD4 and/or CD8 expression; (step 5) activation of human CD8+ T cells was
analyzed for HLA-DR and CD38 expression [42]. Gates
defining HLA-DR and CD38 expression were set with
isotype-matched flourophore-conjugated antibodies.
Viral replication in vitro

The human T-cell line A3.01 (NIH AIDS Reagent Program)
was used to propagate both wild-type and nef-mutant HIV1LAI. Cells were infected with virus stocks at a multiplicity
of infection (MOI) of 0.05 in complete RPMI (containing
10% fetal bovine serum (Hyclone), 50 IU of penicillin per
ml, 50 μg streptomycin per ml, 2 mM L-glutamine, and
1 mM sodium pyruvate) plus 2 μg/ml polybrene at 37°C,
5% CO2 for 4 hours. The cells were washed extensively
with PBS and cultured at 37°C, 5% CO2 in complete
RPMI. Cell cultures were passaged twice weekly at which
time a sample of the culture supernatant was collected for
quantification of viral capsid protein by p24gag ELISA
(HIV-1 p24 Antigen Capture Assay (Advance Biosciences
Library, Inc., #5421).
In vitro analysis of Nef activities

The site directed mutations of nef in pLAINeffsΔ-1,
pLAINeffsΔ-13 and pLAINefP72A/P75A were subcloned
into pLXSN, a retroviral vector for transduction of CEM
T cells and into pcDNA3.1 for transfection into 293T
cells [21]. Assays for CD4 downregulation, MHCI downregulation, and activation of PAK2 were described previously
[21]. Enhancement of virion infectivity was determined by
single infection assays using HeLa-MAGI indicator cells
with virus produced from proviral clones transfected into
293T cells [21,82]. Protein expression was determined by
Western Blot analysis with sheep anti-Nef antibody or
mouse monoclonal anti-Nef [21,83].
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Sequence analysis of plasma virion RNA

Viral RNA was extracted from 20 μl of plasma from infected mice using the QIAamp Viral RNA Mini kit (Qiagen
Sciences, USA). RNA was then reverse transcribed into
cDNA, which was then subjected to nested PCR. The
outer primers for nef amplification are 5′-AGCTTGCT
CAATGCCACAGCC-3′ and 5′-GCTGCATATAAGCAG
CTGCTTTTTG-3′. The inner primers are 5′-TAGAGC
TATTCGCCACATACC-3′ and 5′-GCTTGCTACAAGG
GACTTTCCGC-3′. Gel purified PCR products were
sequenced and the sequences were aligned to HIVLAI sequences to determine if nucleotide changes had occurred.
Statistics

Mann–Whitney tests were performed in Prism version 5
(Graph Pad). All data plotted as mean ± S.E.M.
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